Overview

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

Status:
Completed
Trial end date:
2020-01-10
Target enrollment:
Participant gender:
Summary
A large number of studies have shown that patients feel more satisfied with hydromorphone in the pain management. and a systematic review found that hydromorphone may be better suited than morphine for titration of acute analgesia. However, current researches on intravenous opioid titration for cancer pain such as hydromorphone are relatively insufficient in China. Therefore, a prospective, multi-center, randomized controlled study is conducted to assess the efficacy and safety of comparing patient-controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain.
Phase:
Phase 3
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
Hydromorphone